Militia Capital Management LLC bought a new position in shares of BioAge Labs, Inc. (NASDAQ:BIOA – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 32,286 shares of the company’s stock, valued at approximately $565,000. Militia Capital Management LLC owned approximately 0.07% of BioAge Labs as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of BIOA. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of BioAge Labs in the fourth quarter valued at approximately $1,058,000. Y Intercept Hong Kong Ltd acquired a new stake in BioAge Labs during the 1st quarter worth approximately $3,521,000. Occudo Quantitative Strategies LP bought a new stake in BioAge Labs during the 3rd quarter worth approximately $113,000. Two Sigma Investments LP grew its holdings in BioAge Labs by 54.3% during the 3rd quarter. Two Sigma Investments LP now owns 99,669 shares of the company’s stock worth $586,000 after acquiring an additional 35,068 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in BioAge Labs by 1,230.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,735 shares of the company’s stock valued at $151,000 after acquiring an additional 23,800 shares during the period.
Analyst Ratings Changes
A number of equities analysts have recently commented on BIOA shares. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Roth Capital assumed coverage on BioAge Labs in a research report on Wednesday, May 27th. They set a “buy” rating and a $36.00 target price for the company. Needham & Company LLC started coverage on BioAge Labs in a report on Friday, March 27th. They set a “buy” rating and a $50.00 target price on the stock. Finally, BTIG Research began coverage on BioAge Labs in a research report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.50.
BioAge Labs Stock Performance
Shares of NASDAQ BIOA opened at $21.90 on Friday. The company’s 50 day moving average price is $20.17 and its 200-day moving average price is $19.30. BioAge Labs, Inc. has a 52-week low of $4.11 and a 52-week high of $25.95. The company has a market capitalization of $973.52 million, a P/E ratio of -9.12 and a beta of 0.61.
BioAge Labs (NASDAQ:BIOA – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. Analysts forecast that BioAge Labs, Inc. will post -2.68 earnings per share for the current year.
About BioAge Labs
BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.
At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.
Read More
- Five stocks we like better than BioAge Labs
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.
